Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

392.23 -116.23 (-22.86%)
Streaming Delayed Price Updated: 3:35 PM EDT, Apr 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
MEDP Q1 Deep Dive: Rising Cancellations and Bookings Lag Shape 2026 Outlook
Clinical research company Medpace Holdings (NASDAQ:MEDP) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 26.5% year on year to $706.6 mil... 
Via StockStory
News headline image
Medpace (MEDP) Q1 2026 Earnings Transcript ↗
Medpace (MEDP) Q1 2026 Earnings Transcript 
Via The Motley Fool
These stocks are gapping in today's session ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
Medpace Holdings Inc (NASDAQ:MEDP) Passes Key CAN SLIM Filters Amid Market Caution ↗
Via Chartmill
Medpace Holdings Inc (NASDAQ:MEDP) Passes Key CAN SLIM Growth Filter Amid Technical Caution ↗
Via Chartmill
Medpace Holdings Inc (NASDAQ:MEDP) Stock Falls Despite Strong Q4 Earnings Beat ↗
Via Chartmill
News headline image
Medpace’s (NASDAQ:MEDP) Q1 CY2026 Sales Beat Estimates But Stock Drops 19.8%
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 26.5% year on y... 
Via StockStory
Topics Earnings
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Medpace (MEDP) Q2 2025 Earnings Transcript ↗
Medpace (MEDP) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Medpace (MEDP) Q1 Earnings: What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be reporting earnings this Wednesday after the bell. Here’s what to look for. Medpace beat anal... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Mid-Cap Stock for Long-Term Investors and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
News headline image
3 Market-Beating Stocks with Exciting Potential
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
Topics Credit Cards
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas... 
Via StockStory
News headline image
3 Big Reasons MEDP Should Be On Your Watchlist
Over the past six months, Medpace’s shares (currently trading at $483.21) have posted a disappointing 11.2% loss while the S&P 500 was down 5.5%. This might ... 
Via StockStory
Topics Stocks
News headline image
Q4 Earnings Highs And Lows: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services ind... 
Via StockStory
News headline image
2 Healthcare Stocks with Exciting Potential and 1 We Avoid
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
3 Profitable Stocks for Long-Term Investors
Companies with solid operating margins have a competitive edge, allowing them to reinvest for sustainable expansion. The best of these businesses balance pro... 
Via StockStory
News headline image
Medpace (NASDAQ:MEDP): Strongest Q4 Results from the Drug Development Inputs & Services Group
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how drug development inputs & services stocks fared in Q4,... 
Via StockStory
News headline image
Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health Stocks Trade Down, What You Need To Know
A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited trade policy uncertainty. The move came swiftly after the Supreme Court... 
Via StockStory
Topics Government World Trade
News headline image
Investment Manager Bets Big on Varonis Stock, According to Recent SEC Filing ↗
Varonis Systems provides data security and analytics software to global enterprises, helping organizations manage access and compliance. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
American Capital Management Doubles Down on Novanta Stock, According to Latest SEC Filing ↗
Novanta delivers advanced photonics and precision motion components for medical and industrial OEMs worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Bets on Proto Labs Stock, According to Recent SEC Filing ↗
Proto Labs provides rapid digital manufacturing for engineers and product developers, using an e-commerce-driven, technology-enabled model. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
6 Stock Ideas for the Next 5 Years ↗
Listen in as Motley Fool co-founder Tom Gardner and Chief Investment Officer Andy Cross talk about stocks! 
Via The Motley Fool
Topics Artificial Intelligence
Why Big Stock Swings Like Medpace's 55% Jump Usually Have Clear Causes--Not Market Madness ↗
Understanding the real drivers behind dramatic stock swings can help investors avoid costly mistakes and spot opportunities hidden beneath the headlines. 
Via The Motley Fool
News headline image
The 5 Most Interesting Analyst Questions From Medpace’s Q4 Earnings Call
Medpace’s fourth quarter was marked by robust top-line growth and a significant year-over-year increase in revenue, but the market responded negatively, likely due to rising cancellations and margin... 
Via StockStory
Topics Earnings
News headline image
The Clinical Crisis: A Deep-Dive Into ICON plc (ICLR) Amidst a Transformational Storm
Date: February 12, 2026 Introduction ICON plc (NASDAQ: ICLR) currently finds itself at a pivotal and precarious crossroads. As the world’s second-largest Clinical Research Organization (CRO), the... 
Via Finterra
Topics Artificial Intelligence Fraud Lawsuit
News headline image
1 Cash-Producing Stock with Competitive Advantages and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
News headline image
MEDP Q4 Deep Dive: Cancellations and Metabolic Trial Mix Pressure Margins Despite Strong Growth
Clinical research company Medpace Holdings (NASDAQ:MEDP) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 32% year on year to $708.5 million. The company expects the... 
Via StockStory
Topics Artificial Intelligence
News headline image
Medpace (MEDP) Q4 2025 Earnings Call Transcript ↗
Medpace (MEDP) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Artificial Intelligence Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.